ELISA Kit for S100 Calcium Binding Protein A7 (S100A7)

125-8, 000pg/mL

The minimum detectable dose of this kit is typically less than 50pg/mL

3h

This assay has high sensitivity and excellent specificity for detection of S100 Calcium Binding Protein A7 (S100A7).
No significant cross-reactivity or interference between S100 Calcium Binding Protein A7 (S100A7) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to S100 Calcium Binding Protein A7 (S100A7). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to S100 Calcium Binding Protein A7 (S100A7). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain S100 Calcium Binding Protein A7 (S100A7), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of S100 Calcium Binding Protein A7 (S100A7) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Serum levels of antimicrobial peptides and proteins do not correlate with psoriasis severity and are increased after treatment with fumaric acid esters; Proteomic Signature of Endothelial Dysfunction Identified in the Serum of Acute Ischemic Stroke Patients by the iTRAQ-Based LC–MS Approach; S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL-6 secretion through IκB/NF-κB signaling; Plasma proteins as potential targets of abnormal Savda syndrome in asthma patients treated with unique Uighur prescription; The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function.; A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis; Measurements of AMPs in stratum corneum of atopic dermatitis and healthy skin–tape stripping technique; Comprehensive proteomic profiling of patients' tears identifies potential biomarkers for the traumatic vegetative state;